Arthritis Pain Reliefs Recalled for Improper Storage Temperature Conditions
Family Dollar Stores is recalling BC Arthritis Pain Fast Pain Relief and Good Sense Arthritis Caplet due to improper storage conditions. Products were distributed nationwide from April 30 through June 10, 2022.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall for manufacturing deviation (improper storage conditions). Per the rubric, risk-of-harm products without reported injuries are classified as High (Level 3).
Plain-English summary
Family Dollar Stores, Llc. is recalling two arthritis pain relief products: BC Arthritis Pain Fast Pain Relief 24 Caplets (SKU 999839) and Good Sense Arthritis Caplet 24 Count (SKU 914771). These products were distributed to specific Family Dollar Stores nationwide from April 30, 2022 through June 10, 2022.
The recall was initiated because the products were subjected to a Current Good Manufacturing Practice (CGMP) deviation. Specifically, the products were held outside appropriate storage temperature conditions during distribution.
For more information about this recall, consumers may contact Family Dollar Stores or visit the FDA's Drug Safety and Availability page.
The recalled product
- Product
- BC ARTHRITIS PAIN FAST PAIN RELIEF 24CT SKU 999839 GOOD SENSE ARTHRITIS CAPLET 24 CT SKU 914771 distributed to specific Family Dollar Stores 04/30/2022 through 06/10/2022.
- Manufacturer
- Family Dollar Stores, Llc.
- Category
- Drug — Pain Relief
- Hazard
- improper-storage
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- SKUs: 999839
- 914771
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27